Zanidatamab
HER2-Positive Solid Tumors
Iambic Therapeutics, Incmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the HER2-Positive Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
M802 Wuhan YZY Biopharma Co., Ltd. | Phase 1 | CC |
TRASTUZUMAB Iambic Therapeutics, Inc | Phase 1 | CC |
Pembrolizumab Iambic Therapeutics, Inc | Phase 1 | CC |
T-Dxd Iambic Therapeutics, Inc | Phase 1 | CC |
Carboplatin Iambic Therapeutics, Inc | Phase 1 | CC |
View all 10 →
Same molecule, other indications
Zanidatamab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →